Company News-Bio-Thera Solutions, Ltd.

The European Commission (EC) Approves Bio-Thera Solutions’ BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

04-142023

Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting

GUANGZHOU, CHINA, April 14, 2023 – Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, tod...
03-132023

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, to...
03-082023

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, to...

上一页 ···13 14 15 16 17 ··· 下一页